Measuring mild cognitive impairment in patients with Parkinson's disease. Issue 5 (20th March 2013)

• Record Type: Journal Article
• Authors: Marras, Connie; Armstrong, Melissa J.; Meaney, Christopher A.; Fox, Susan; Rothberg, Brandon; Reginold, William; Tang‐Wai, David F.; Gill, David; Eslinger, Paul J.; Zadikoff, Cindy; Kennedy, Nancy; Marshall, Fred J.; Mapstone, Mark; Chou, Kelvin L.; Persad, Carol; Litvan, Irene; Mast, Benjamin T.; Gerstenecker, Adam T.; Weintraub, Sandra; Duff‐Canning, Sarah
• Is Part Of: Movement disorders. Volume 28:Issue 5(2013)
• Page Start: 626
• Page End: 633
• Publication Date: 2013-03-20
• Subjects: Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.25426
• Languages: English
• ISSNs: 0885-3185

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <p>We examined the frequency of Parkinson disease with mild cognitive impairment (PD‐MCI) and its subtypes and the accuracy of 3 cognitive scales for detecting PD‐MCI using the new criteria for PD‐MCI proposed by the Movement Disorders Society. Nondemented patients with Parkinson's disease completed a clinical visit with the 3 screening tests followed 1 to 3 weeks later by neuropsychological testing. Of 139 patients, 46 met Level 2 Task Force criteria for PD‐MCI when impaired performance was based on comparisons with normative scores. Forty‐two patients (93%) had multi‐domain MCI. At the lowest cutoff levels that provided at least 80% sensitivity, specificity was 44% for the Montreal Cognitive Assessment and 33% for the Scales for Outcomes in Parkinson's Disease‐Cognition. The Mini‐Mental State Examination could not achieve 80% sensitivity at any cutoff score. At the highest cutoff levels that provided specificity of at least 80%, sensitivities were low (≤44%) for all tests. When decline from estimated premorbid levels was considered evidence of cognitive impairment, 110 of 139 patients were classified with PD‐MCI, and 103 (94%) had multi‐domain MCI. We observed dramatic differences in the proportion of patients who had PD‐MCI using the new Level 2 criteria, depending on whether or not decline from premorbid level of intellectual function was considered. Recommendations for methods of operationalizing decline from premorbid levels constitute an unmet need. Among the 3 screening tests examined, none of the instruments provided good combined sensitivity and specificity for PD‐MCI. Other tests recommended by the Task Force Level 1 criteria may represent better choices, and these should be the subject of future research. © 2013 <italic>Movement</italic> Disorder Society</p> </abstract>